Navigation Links
Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
Date:7/16/2008

LA JOLLA, Calif., July 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) announced today that the distribution of SF-1019 in the State of Utah is anticipated to begin shortly through Renewed Hope Clinic in Beaver, Utah.

Immunosyn is negotiating an exclusive license agreement for the administration and distribution of SF-1019 in the State of Utah with Utah Biopharmaceutical Laboratories, LLC.

Immunosyn has been advised by Argyll Biotechnologies, LLC, the licensor of SF-1019, Immunosyn's strategic partner and its largest shareholder, that Argyll Biotech is negotiating a three-party agreement with its current domestic third party manufacturer and Utah Biopharmaceutical Laboratories for Utah Biopharmaceuticals Laboratories to be a third party manufacturer of SF-1019 in the State of Utah. Argyll Biotech has worked for several years on developing the manufacturing processes, protocols, safety procedures and guidelines for SF-1019. Immunosyn, together with Argyll Biotech and Utah Biopharmaceutical Laboratories, is working to finalize Distribution Management and Information Component Systems that will be implemented to define protocols to assure patient safety and regulatory compliance in Utah prior to treatment commencing.

The combination of the proposed license and manufacturing agreements will allow for SF-1019 to be administered in the State of Utah exclusively by Utah Biopharmaceutical Laboratories through Renewed Hope Clinic which is located in Beaver, Utah.

"I am excited to have the ability to treat patients with this therapeutic modality, which is not yet available elsewhere in the U.S. My review of the scientific background, preclinical testing, initial safety evaluations and studies performed under compassionate waivers, coupled with the therapeutic benefits I have witnessed, give me confidence in the benefit my patients will receive from SF-1019 treatment," said Mitchell J. Melling, MD, Manager of Utah Biopharmaceutical Laboratories, LLC.

Stephen D. Ferrone, President and CEO of Immunosyn, stated, "Utah Biopharmaceutical Laboratories sought the ability to distribute SF-1019 in the State of Utah as a result of the compelling desire of patients who are seeking this treatment after their having failed conventional, FDA approved therapy. This patient demand stemmed from the perceived benefit of treatment in patients who participated in early preclinical studies and who desire ongoing access to SF-1019 to alleviate their symptoms."

Ferrone added, "Argyll Biotech advises us that they plan to continue the process to obtain full regulatory approvals for the marketing of SF-1019 in both Europe and the U.S."

"This is an exciting early-stage development as this puts revenue producing capabilities within short-term range for the company," stated Douglas A. McClain, Jr., Chairman of the Board and CFO of Immunosyn.

About Utah Biopharmaceutical Laboratories, LLC

Utah Biopharmaceutical Laboratories was organized for the purpose of manufacturing SF-1019 for administering and distributing by United Biopharmaceutical Laboratories through the Renewed Hope Clinic under the direction of Mitchell J. Melling, MD in the State of Utah.

About Renewed Hope Clinic

Located in Beaver, Utah at 95 North 400 East, Renewed Hope Clinic is managed by Mitchell Melling, MD who is Board Certified in Family Practice in the State of Utah. Renewed Hope Clinic is a family practice center, emphasizing treatment of autoimmune and infectious diseases.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the U.S. and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immunosyn Corporation Names Stephen Ferrone as CEO
2. Immunosyn Corporation to Begin Trading
3. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
4. Immunosyn Announces the Successful Completion of First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. Douglas A. McClain, Jr. Resumes CFO Duties at Immunosyn
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused on ... efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, Jr. ... honored to team up with Upstage Lung Cancer in order to make major strides ...
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... set up in 2006 as a non-profit organization to unite pharmaceutical and healthcare ...
(Date:12/8/2016)... ... ... STAT courier is pleased to announce that due to customer demand, as ... their presence in Dallas. One of the most exciting parts for STAT is that ... Dallas and Forth Worth market. STAT takes pride in treating their employees with integrity ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... the global optical transceiver market to grow at a CAGR of ... the present scenario and the growth prospects of the global optical ... considers the revenue generated from the shipment of optical transceivers worldwide ...
(Date:12/9/2016)...  RxWiki Inc., a digital health company that powers ... thousands of pharmacies through its Digital Pharmacist SaaS platform, ... "50 on Fire" Award in the Health and Life ... the award as one of Austin,s fastest growing companies," ... RxWiki. "Our platform gives independent retail pharmacies the digital ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology: